Provider review
Lighter You Review: The Peptides Now Have Names, and Two Different Prices Each
On August 7 Lighter You sold a peptide program without naming a single peptide. Re-checked on August 25, it names them — sermorelin, NAD+ in three forms, B12 MIC — each with its own starting price, plus a new sub-brand called TidesRx. That is a real improvement. It also created a new problem, because the two pages quote different prices for the same three products on the same day.
Lighter You is better than it was three weeks ago and still cannot be evaluated from the outside. On August 7 it sold a formulary of at least eight compounded ingredients as four words on a card and named none of them. On August 25 it names sermorelin, NAD+ and B12 MIC, prices each one, and has built a whole sub-brand around them — a real improvement, made without being asked. What it has not fixed is the part a buyer has to act on. The two pages selling those three products quote different prices for them on the same day. Glutathione and methylene blue are still nowhere a buyer would look. The only testing sentence promises purity, which is not potency. No state is named, no pharmacy is named, and a satisfaction guarantee is advertised on one page and denied on another. The screening behind the button remains the best thing here — it refuses sermorelin under 25, again for elevated IGF-1 or prolactin, and handles each ingredient separately, which is more clinical thought than most of this category shows.
Worth trusting if
- You want to see a figure before you answer anything, because every program and every peptide card carries a Starting At price on the storefront.
- You want the medicine screened rather than rubber-stamped, because the intake refuses sermorelin under 25 and again for elevated IGF-1 or prolactin, and handles each ingredient separately.
- You want to know which molecules are in the program, because sermorelin, NAD+ in three forms and B12 MIC are now named on the page rather than hidden behind a button.
Be skeptical if
- You need to know what you will be charged, because Lighter You's own home page and TidesRx page quote different starting figures for the same three products on the same day.
- You expect a refund if the treatment does not suit you, because the FAQ advertises a 30-day satisfaction guarantee and the refund policy says in capitals that no refund is ever issued on cancellation.
- You want to check the state rules before you start, because the only geographic statement is that it is not available in all 50 states, and no state is named anywhere.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.lighteryou.co. A link is not a recommendation to take anything.
Provenance
What Lighter You actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Peptides & Longevity program — sermorelin component — Read 2026-08-07: sermorelin had no price of its own, only the program card at "Starting at $145". Re-checked 2026-08-25: sermorelin now has its own card, and the two pages disagree — the home page says "Starting at $229" and the TidesRx page says "Starting at $175" for the same product on the same day. No figure is filed here, because a price a company's own two pages contradict is not a price. No billing cycle or dose tier is published on either.
- Peptides & Longevity program — NAD+ component — Read 2026-08-07: no per-molecule price was published. Re-checked 2026-08-25: NAD+ now has three cards of its own — an injection, a nasal spray and an oral form. The nasal spray and the oral form read "Starting at $229" on both pages. The injection does not: the home page says "Starting at $229" and the TidesRx page says "Starting at $199", so no figure is filed for it.
- Peptides & Longevity program — glutathione component — No price of its own on either date. Glutathione is still not named anywhere a buyer would look — it appears only inside the intake's own eligibility rules, and the August 25 re-check found it absent from the new peptide cards and from the TidesRx catalog alike.
- Weight Loss program (MACRO-Dosing MWL) and Microdosing program — Read 2026-08-07: "Starting at $169" on both the Weight Loss and Microdosing cards, against a site-wide banner advertising "Starting at $99". Re-checked 2026-08-25: the weight-loss card still reads "Starting at $169" and the banner still reads "Starting at $99", but the microdosing card has moved to "Starting at $96" while a separate Microdose GLP-1 product reads "Starting at $179", and GLP-1 tablets have appeared at "Starting at $249". No figure is described as introductory or ongoing on either date, and "per month", "first month" and "intro" still do not appear.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 4 products reviewed here. The evidence belongs to the molecule, not to Lighter You.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Lighter You’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Peptides & Longevity program — sermorelin componentSermorelin · Compounded (503A)No trial supports this claim
“Science-backed peptides for energy, recovery, and healthy aging.”
Read on the Lighter You site, August 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005 — a study of a PEG-conjugated GHRH analog measuring growth hormone stimulation in healthy young and elderly subjects. Every one of the 19 measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures energy, recovery or healthy aging as an outcome in healthy adults. A parallel search of ClinicalTrials.gov for sermorelin as an intervention returned 27 studies.
"Science-backed" is the entire claim, it is four words long, and it is made for a formulary the buyer cannot see. Sermorelin is a growth-hormone-releasing hormone analog and it does stimulate pituitary GH release — a real mechanism, which is why it was used as a diagnostic agent. The literature attached to it stopped producing randomized trials in 2005, and none of those trials measured energy or recovery in healthy adults. A claim that names no molecule cannot be checked by the person paying for it, which is the deeper problem here: the reader has no way to know what "science-backed" is supposed to refer to.1,2
Peptides & Longevity program — NAD+ componentNicotinamide adenine dinucleotide (NAD+) · Compounded (503A)No trial supports this claim
“Science-backed peptides for energy, recovery, and healthy aging.”
Read on the Lighter You site, August 2026
No trial for this use
As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" in the title or abstract, combined with an injected route (subcutaneous, injection or intravenous) and filtered to the randomized-controlled-trial publication type, returned exactly one record: a 2026 placebo-controlled trial of NAD+ in heart failure caused by ischemic cardiomyopathy. Removing the route filter raises the count to 70, none of which tests an injected preparation for energy or healthy aging. A parallel ClinicalTrials.gov search for NAD+ as an intervention returned 261 studies, across conditions including lupus, mild cognitive impairment and hepatitis C.
NAD+ is a coenzyme, it does decline with age, and none of that is disputed. The claim on sale is that an injected preparation delivers "energy" and "healthy aging", and the randomized evidence for the injected route is a single trial in heart-failure patients. Note that NAD+ is not a peptide — it is a dinucleotide — so the heading "Science-backed peptides" is not even the right category for the largest component of the program it describes.3
Peptides & Longevity program — glutathione componentGlutathione · Compounded (503A)No trial supports this claim
“Science-backed peptides for energy, recovery, and healthy aging.”
Read on the Lighter You site, August 2026
No trial for this use
What the trials show for Glutathione
As of August 2026, a PubMed search for glutathione combined with subcutaneous and filtered to the randomized-controlled-trial publication type returned nine records, and reading them matters more than counting them. Four are veterinary — dairy cattle and dairy goats given selenium or trace-element supplements. In the remaining five, glutathione is a blood marker that was measured rather than a drug that was injected: a schistosomiasis vaccine trial, a methyl-B12 trial in children with autism, a vegetarian-diet trial, an allergen-immunotherapy study and a study of heparin after surgery. None tests injected glutathione as an intervention in healthy adults.
Glutathione is genuinely the principal intracellular antioxidant and it genuinely draws down under oxidative load. What has not been shown is that injecting it produces "energy" or "recovery" in a healthy adult, and the randomized literature for the injected route contains nothing in that population. Glutathione is a tripeptide, so unlike NAD+ it at least belongs under the word "peptides" — but the buyer is never told it is in the program.4
Weight Loss program (MACRO-Dosing MWL) and Microdosing programSemaglutide and tirzepatide · Compounded (503A)Claim reaches past the trials
“Through our trusted pharmacy partners, we offer a range of prescription wellness therapies, including GLP-1 medications such as tirzepatide and semaglutide, targeted peptide therapies, and medications for men's and women's health. Every treatment plan is prescribed by a licensed healthcare provider based on your individual health needs and clinical evaluation.”
Read on the Lighter You site, August 2026
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved once-weekly semaglutide 2.4 mg product in adults with overweight or obesity. No compounded preparation has been through a registered trial.
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved tirzepatide product in adults with obesity or overweight.
The FAQ answer itself is accurate and appropriately hedged, and the footer carries a correct compounding disclaimer. What overstates sits a few hundred pixels away: an interactive slider on the same page that, for a 220 lb starting weight, returns "Weight you could lose: 48 lbs" — roughly 22% of body weight — with no drug named, no dose, no time period and no indication that it describes a trial result rather than an expectation. The molecules underneath have genuine phase 3 evidence; the number the slider produces is presented as a personal projection with nothing attached to it.5,6,7
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. The word "pharmacy" occurs twice in Lighter You's entire published bundle, in the phrases "a partner pharmacy" and "our trusted pharmacy partners", and the how-it-works step says only that "the prescription is sent to a partner pharmacy for fulfillment." The clinical side is disclosed slightly better, though never on Lighter You's own pages: the footer links its telehealth consent to openloophealth.com, and the intake at shop.lighteryou.co runs on the same white-label platform, so OpenLoop is identifiable as the telehealth partner by following the link rather than by being told. The more useful discovery is what sits behind the buttons. The `/go` redirect chunk maps each plan's button to an intake product ID, and those IDs resolve through the platform's own API to named templates: weight loss to "MACRO-Dosing MWL Initial Intake", microdosing to "MICRO-Dosing GLP-1/GIP Initial Intake", men's health to "ED Initial Intake", and both peptides AND women's health to "Metabolic and Cellular Optimization Initial Intake". That last mapping is a fault worth naming: a patient clicking "Women's Health" is sent to the NAD+ and sermorelin questionnaire. All four templates were read on 2026-08-07.
Read on the Lighter You site, August 2026.
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described program, not a document.
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
This changed between checks and both readings are kept. Read on August 7, 2026: nothing at all, measured rather than assumed. Lighter You's whole site was served from a client bundle of 495,437 characters, and across it the strings "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occurred ZERO times. Re-checked on August 25, 2026: the new TidesRx pages carry one sentence — "Compounded in licensed facilities with third-party purity verification on every lot" — and badge six pipeline products "503A RECOMMENDED". That is a testing claim where there was none, so this field now reads true. It is worth exactly what it says and no more. No standard is named, no laboratory is named, no potency tolerance is given, no lot report is published, and "purity" is not "potency" — purity says what else is in the vial, potency says how much of the drug is. The one thing a buyer most needs to check is still the thing nobody publishes. The pharmacy is still unnamed on both dates. Pages carry a LegitScript seal served under certificate id 51449551; LegitScript's public checker is bot-gated and returned no certification record when queried on August 7, 2026, so the seal is reported here as displayed and not as confirmed — neither claimed nor denied.
Read on the Lighter You site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Not disclosed. Lighter You states only that it is "[n]ot available in all 50 states" and names no state anywhere
Read the full licensing claim
The single sentence Lighter You publishes about geography is in its footer disclaimer: "Not available in all 50 states. Please visit our website for full details, applicable restrictions, and important drug safety information." That sentence is itself printed on the website, so the instruction is circular. Searched across the whole client bundle on 2026-08-07, no state name appears anywhere — not as an exclusion list, not as a coverage list, not in the FAQ. The how-it-works copy does acknowledge that a clinician conducts "a synchronous audio or video visit when required by applicable state law", so the company knows state rules vary; it simply does not say which states they are. This review therefore lists no excluded states, and that is because nothing has been disclosed — not because coverage has been checked and found complete. Nothing here was checked against a state board of pharmacy, and no pharmacy is named to check.
Read on the Lighter You site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Lighter You
We went through Lighter You’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Read the card for the program you want. Every one carries a Starting At figure before you answer anything.
- Press Get Started, which hands you straight to a separate intake site — no account, no login screen.
- Screen one asks for your first name, last name, phone number and email address, and a consent box.
- Screen two asks for your street address, city, state and ZIP code, plus a consent to be texted about your care.
- This walk stopped at the address screen; the clinical questions sit behind it.
- Every figure on the site is a Starting At. Nothing anywhere identifies a figure as a first month or as an ongoing rate, and the words per month, first month and intro do not appear.
- The same three products are priced differently on Lighter You's own two pages. The home page carousel and the TidesRx catalog quote different starting figures for the NAD+ injection, sermorelin and B12 MIC, read the same day.
- The intake takes your name, phone number, email and full shipping address before it asks a single question about your health.
- There is no account gate at the start. Pressing Get Started opens the questionnaire directly, which is a change from an earlier check where the route ran through a login.
- The card marked Women's Health reads Coming Soon and its route still opens the NAD+ and sermorelin questionnaire, which is the peptides intake under a different label.
- The intake page carries its own banner price, so the first thing you see after leaving the storefront is a Starting At figure again rather than a total.
Assessment
What holds up, and what does not
- The intake is the best thing here. It screens per ingredient, not per program — its own rules include "Not eligible for sermorelin under age 25" and separate sermorelin exclusions for elevated IGF-1 and elevated prolactin.
- It also disqualifies for uncontrolled diabetes above 10% A1C, routine opiate use, binge drinking and thyroid medication, each mapped to a named ingredient rather than a blanket refusal.
- The compounding disclaimer is correct and sits in the footer of every page: FDA "does not evaluate compounded products for safety, effectiveness, or quality."
Show 4 more
- The how-it-works copy concedes that a synchronous audio or video visit is required where state law demands one, rather than implying a form is always enough.
- Cold-chain shipping is stated as included, along with dietitian visits and care coaching, so the program fee is not obviously a medication-only price.
- The FAQ answer on medications is honest about the range offered and attributes prescribing to a licensed provider after clinical evaluation.
- It started naming its peptides. On 2026-08-07 the program was four words on a card; re-checked 2026-08-25, sermorelin, NAD+ in three forms and B12 MIC each have a card, a price and a line of description. That is the single biggest improvement this site has made.
- Its own two pages price the same three products differently on the same day. Sermorelin, the NAD+ injection and B12 MIC each carry one figure on the home page and a lower one on the TidesRx page, read 2026-08-25.
- Glutathione and methylene blue are still not named anywhere a buyer would look. They appear only inside the intake's own eligibility rules, on both check dates.
- The "Women's Health" button still resolves to the same intake product ID as the peptides program — the NAD+ and sermorelin questionnaire. Re-checked 2026-08-25, unchanged, even though the card itself now reads "Coming Soon".
Show 4 more
- The only testing claim is one sentence about third-party purity verification. Purity is not potency, no standard or laboratory is named, and no lot report is published.
- The homepage FAQ promises "a 30-day satisfaction guarantee." The refund policy says "IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION" outside medical disqualification.
- A slider returns "Weight you could lose: 48 lbs" for a 220 lb input — about 22% of body weight — with no drug, dose, time period or source attached.
- It will not name a state. The only geographic statement is "[n]ot available in all 50 states. Please visit our website for full details" — printed on the website.
Verdict
The bottom line
Ask which page's price you are being charged. The home page and the TidesRx page quoted different figures for sermorelin, the NAD+ injection and B12 MIC on the same day, and nothing on either says which one governs your card. Then ask what the potency tolerance is, because the only quality sentence published promises purity instead.
Opens www.lighteryou.co. A link is not a recommendation to take anything.
Re-checked 2026-08-25: the peptides have names now, and two prices each
This review was first published on August 7, 2026, and its headline finding was that Lighter You sold a peptide program without naming a peptide. That is no longer true, and saying so first is the point of re-checking.
Walked again on August 25, the home page carries a peptide carousel with a card each for Sermorelin, NAD+, an NAD+ nasal spray, an oral NAD+ and B12 MIC, every one with a name, a line of description and its own "Starting at" figure. A sub-brand has appeared alongside it — TidesRx, at lighteryou.co/tidesrx — with a catalog page, a research page and an FAQ. A company that names its formulary is a better company to buy from than one that does not, and Lighter You did this without being made to.
Two things stop that being the end of the story.
The first is that the two pages disagree about money. On the same day, the home page and the TidesRx page quote different starting figures for the NAD+ injection, for sermorelin and for B12 MIC. The nasal spray and the oral form agree; those three do not. Neither page says which one governs a card, and no figure for those three is filed as a price on this review, because a price a company's own two pages contradict is not a price.
The second is what still is not named. Glutathione and methylene blue are in the formulary — the intake's own eligibility rules say so — and they appear on neither page. So the improvement is real and it is partial: the products with cards got named, and the ones inside the program did not.
Everything below this heading was read on August 7, 2026, and is kept with that date. The evidence findings have not moved, because the trials have not.
Full analysis — 5 more sectionsA claim with no noun in it · What the evidence says about the three that matter · The intake is better than the website · Two things that do not survive being read side by side · What cannot be evaluated from outside
A claim with no noun in it
Here is the entire published case Lighter You made for its peptide program on August 7, 2026, quoted in full: "Science-backed peptides for energy, recovery, and healthy aging."
That was it. There was no product page. There was no molecule named on the card, in the FAQ, in the footer, or in the terms. Searched across the 495,437-character bundle that rendered every route of the site that day, the strings "sermorelin", "NAD" and "glutathione" occurred zero times each. The FAQ's answer on what was offered got as specific as "targeted peptide therapies".
So a reader was asked to accept "science-backed" about an unnamed set of molecules. That is not a claim anyone can check, and being uncheckable is worse than being wrong — a wrong claim can at least be corrected. Three weeks later most of that set has names on it, which is what correcting looks like.
The molecules are knowable, though, and it is worth showing the working because the method is the point.
Lighter You's plans do not link to product pages; each button goes to `/go?product=peptides`. The small JavaScript chunk behind that route contains a hard-coded map from each product name to a checkout URL. For `peptides` it points to `shop.lighteryou.co/intake?productId=UHJvZHVjdDoxNzg=`, and that identifier is base64 for "Product:178". Asking the platform's own public template API what Product:178 is returns an intake called "Metabolic and Cellular Optimization Initial Intake", carrying the program code `nad_sermorelin`.
And the intake enumerates the formulary itself, because it has to — it asks which of these you are allergic to, and which you have recently taken. The list: NAD, sermorelin, B12/B12-MIC, methylene blue, glutathione, L-carnitine, Lipo-C, and Lipo-Mino-Mix-C.
Eight ingredients. Four words of marketing copy. Re-checked on August 25, five of the eight have cards of their own and three still do not — glutathione, methylene blue and the Lipo blends. The same intake, at the same product identifier, is still what the Women's Health button opens.
What the evidence says about the three that matter
Sermorelin. A growth-hormone-releasing hormone analog, the 1-29 fragment, which does prompt the pituitary to release growth hormone. That mechanism is real and is why the molecule existed, largely as a diagnostic agent. As of August 2026, a PubMed search for sermorelin filtered to randomized controlled trials returns 19 records, and the most recent was published in 2005 — a study of a PEG-conjugated GHRH analog measuring growth hormone stimulation in healthy young and elderly subjects. 1 Every one of the nineteen measures GH secretion, growth in children, or a diagnostic response. None measures energy, recovery or healthy aging in healthy adults. ClinicalTrials.gov lists 27 sermorelin studies. 2
NAD+. As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" combined with an injected route and filtered to randomized controlled trials returns exactly one record: a 2026 placebo-controlled trial in heart failure caused by ischemic cardiomyopathy. 3 Worth noting in passing that NAD+ is a dinucleotide rather than a peptide, so the heading "Science-backed peptides" is the wrong category for it.
Glutathione. A tripeptide, so at least the heading fits. As of August 2026, a PubMed search for glutathione with subcutaneous, filtered to randomized trials, returns nine records — of which four are veterinary studies in dairy cattle and goats, and in the other five glutathione is a blood marker somebody measured rather than a drug somebody injected. 4 None tests injected glutathione as an intervention in healthy adults.
Three molecules, and between them one randomized injected-route trial, in cardiology patients, plus a sermorelin literature that stopped twenty-one years ago.
The intake is better than the website
This is the genuinely surprising part, and it deserves its own section because it cuts against everything above.
The questionnaire behind that button is not a formality. It performs per-ingredient disqualification, not per-program. Its own rules include a hard age floor — "Not eligible for sermorelin under age 25" — and separate sermorelin exclusions for elevated IGF-1 and elevated prolactin, which are precisely the two markers a clinician should care about before stimulating the growth-hormone axis. There are further ingredient-specific refusals for uncontrolled diabetes above 10% A1C, routine opiate use, binge drinking as defined by CDC guidelines, and thyroid medication. Glutathione is separately refused for asthma or COPD. Methylene blue is refused alongside serotonergic medications.
Somebody with clinical training built that. It is more careful than the screening on several better-known companies, and it is invisible to anyone who has not decoded a base64 product ID.
Which produces the strange shape of this review: the medicine appears to be handled with more care than the marketing, and the buyer can only see the marketing.
Two things that do not survive being read side by side
The guarantee. The homepage FAQ, under "Can I cancel anytime?", says: "Yes. Membership is month-to-month with a 30-day satisfaction guarantee."
The cancellation and refund policy, on the same domain, says: "Other than cancellation due to medical disqualification, IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES." The capitals are Lighter You's. The only refund the policy allows is for disqualification by a provider, and cancellation requires 72 hours' notice before the billing date or you are charged for another cycle.
A satisfaction guarantee that returns no money in any circumstance where you are merely dissatisfied is not a satisfaction guarantee. Both sentences are live.
The button. In the redirect map, `womens-health` resolves to Product:178 — the same identifier as `peptides`, the NAD+ and sermorelin intake. There is no women's-health template behind the women's-health card. (For completeness: `mens-health` resolves to Product:168, whose template is named "ED Initial Intake".)
That is a wiring fault rather than a claim, and it may be fixed by the time you read this. It is recorded here with its date because it is exactly checkable: follow the button and see where you land. It was checked again on August 25 and it had not been fixed — the Women's Health card now reads "Coming Soon", and the route behind it still opens the NAD+ and sermorelin intake.
What cannot be evaluated from outside
Two absences close this out, and both were measured rather than inferred.
On August 7 there was no testing disclosure at all. Across the whole bundle, "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occurred zero times. Re-checked on August 25, one sentence has appeared on the TidesRx pages: "Compounded in licensed facilities with third-party purity verification on every lot." Read what it promises. Purity says what else is in the vial; potency says how much of the drug is in it, and potency is the number you have no other way to check. No standard is named, no laboratory is named, no tolerance is given and no lot report is published. Lighter You still never states whether its preparations come from a 503A pharmacy or a 503B outsourcing facility, and it still never names the pharmacy — "pharmacy" occurred twice in the whole site on the first read, both times as "partner pharmacy". Its pages carry a LegitScript seal under certificate id 51449551; LegitScript's public checker is bot-gated and returned no record when queried, so that seal is reported here as displayed and not as confirmed.
And there is no state list. The only geographic statement anywhere is the footer's "Not available in all 50 states. Please visit our website for full details, applicable restrictions, and important drug safety information" — an instruction to visit the website, printed on the website. No state name appears anywhere in the bundle.
Lighter You is not obviously doing anything wrong. That is rather the difficulty: from the outside, there is no way to establish that it is doing anything right either, beyond an intake form you have to reverse-engineer a button to find.
Questions
Frequently asked questions
Which peptides does Lighter You actually sell?
Most of them are named now. Read on August 7, 2026, the site's only description was "Science-backed peptides for energy, recovery, and healthy aging," and the words sermorelin, NAD and glutathione appeared zero times across the whole published site. Re-checked on August 25, 2026, the home page and a new sub-brand called TidesRx each carry cards for Sermorelin, NAD+, an NAD+ nasal spray, an oral NAD+ and B12 MIC. Three ingredients are still unnamed on both pages — glutathione, methylene blue and the Lipo blends — and they are knowable only from Lighter You's own signup flow: the peptides button opens an intake called "Metabolic and Cellular Optimization Initial Intake", program code nad_sermorelin, whose eligibility rules name NAD, sermorelin, B12/B12-MIC, methylene blue, glutathione, L-carnitine, Lipo-C and Lipo-Mino-Mix-C.
Is there evidence behind "science-backed peptides"?
Not for the outcomes advertised. Sermorelin: as of August 2026, 19 randomized trials in PubMed, the newest from 2005, all measuring growth hormone secretion, growth in children, or a diagnostic response — none measuring energy, recovery or healthy aging in healthy adults. Injectable NAD+: one randomized injected-route trial, in heart failure caused by ischemic cardiomyopathy. Injected glutathione: nine randomized trials match the route, four of them veterinary, and in the rest glutathione was measured rather than injected. The mechanisms these molecules act on are real. The outcomes on the card have not been tested.
What does Lighter You actually cost?
There is still no price you can plan against, and now there are two of them. Every figure on the site is a "Starting at", and on August 25, 2026 the home page and the TidesRx page quoted different starting figures for the same three products — the NAD+ injection, sermorelin and B12 MIC — read within minutes of each other. The NAD+ nasal spray and the oral NAD+ agree on both pages. Nothing on either page says which figure governs your card. Two of five programs are priced only as "Membership + Medication Cost", which is a format rather than a figure, and the words "per month", "first month" and "intro" appear nowhere, so no figure is identified as a first month or as an ongoing rate. We don't print a number we would have to invent, and we don't file a price a company's own two pages contradict.
Does the "Women's Health" button work?
It goes somewhere, but not where the label says. In Lighter You's own redirect map, read on August 7, 2026 and again on August 25, the womens-health product resolves to the same intake identifier as the peptides program — Product:178, the "Metabolic and Cellular Optimization" questionnaire for NAD+ and sermorelin. There is no separate women's-health template behind it, and the card on the home page now reads "Coming Soon" while the route stays live. For completeness, the mens-health card resolves to Product:168, whose template is named "ED Initial Intake". This is a wiring fault rather than a claim; the check is to follow the button and see where you land.
Is there really a 30-day satisfaction guarantee?
Two Lighter You pages disagree. The homepage FAQ says "[m]embership is month-to-month with a 30-day satisfaction guarantee." The cancellation and refund policy says, in capitals, "[o]ther than cancellation due to medical disqualification, IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES." The only refund the policy contemplates is disqualification by a provider, and cancellation must reach the company at least 72 hours before the billing date or another cycle is charged. Both pages were live on August 7, 2026.
What does Lighter You publish about testing or the pharmacy?
One sentence about testing, and nothing about the pharmacy. Read on August 7, 2026 there was nothing at all: across the 495,437-character bundle that rendered the site, the strings "tested", "sterile", "USP", "potency", "purity", "certificate of analysis", "COA", "503A" and "503B" occurred zero times. Re-checked on August 25, the TidesRx pages say the products are "[c]ompounded in licensed facilities with third-party purity verification on every lot". That is one claim, and purity is not potency — purity is about what else is in the vial, potency is about how much of the drug is. No standard, no laboratory, no tolerance and no lot report accompany it. The pharmacy is still not named on either date. The footer does carry a correct disclaimer that FDA "does not evaluate compounded products for safety, effectiveness, or quality" — which describes what has not been checked, not what has.
Has Lighter You had an FDA warning letter?
No match was found. On August 7, 2026 we screened the 113 FDA warning letters from the telehealth enforcement waves for "Lighter You", "lighteryou" and "OpenLoop" — the last being the telehealth partner its footer links to — on full company names rather than fragments. None appears. That set covers the telehealth enforcement waves rather than every letter FDA has issued, and the absence of a letter is not a clean inspection record. In this case there is an extra limit: the pharmacy that would be inspected is not named.
Glossary
Key terms
Show definitions
- 503A compounding pharmacy
- A state-licensed pharmacy preparing a medicine against a prescription for a named patient. Compounded preparations are not FDA-approved and FDA does not review them for safety, effectiveness or quality. Lighter You never states which category its preparations come from — "503A" and "503B" appear nowhere on its site.
- GHRH analog
- A molecule shaped like growth-hormone-releasing hormone, which prompts the pituitary to release growth hormone rather than supplying it directly. Sermorelin is the 1-29 fragment. Elevated IGF-1 and prolactin are the markers that make stimulating that axis inadvisable — which is why Lighter You's intake screens for both.
- Lipotropic injection
- An injected blend of methionine, inositol and choline, usually with vitamin B12 — sold here as B12-MIC, Lipo-C and Lipo-Mino-Mix-C. The individual compounds have literatures of their own; the blends as sold have no registered randomized trial.
- Certificate of analysis
- A lot-specific laboratory report stating what was tested and what the results were. A seller describing a testing program and a seller publishing a certificate you can read are making different claims. Lighter You makes neither.
- Per-ingredient screening
- An intake that refuses one component of a program while allowing the others, rather than accepting or rejecting a patient wholesale. Lighter You's questionnaire does this — declining sermorelin for a patient under 25 or with raised IGF-1 while leaving the rest of the formulary available.
Compare
Others selling what Lighter You sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Lighter You's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 7 sources
- Munafo A, Nguyen TX, Papasouliotis O, et al. (2005). Polyethylene glycol-conjugated growth hormone-releasing hormone is long acting and stimulates GH in healthy young and elderly subjects.. European journal of endocrinology 153(2):249-56. https://pubmed.ncbi.nlm.nih.gov/16061831/
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; and ClinicalTrials.gov search: intervention "sermorelin" — 27 studies. Both run 2026-08-07. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- Yu X, Xu J, Cao J (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.. American journal of cardiovascular drugs : drugs, devices, and other interventions 26(1):97-106. https://pubmed.ncbi.nlm.nih.gov/40954388/
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND subcutaneous[tiab] AND randomized controlled trial[pt] — 9 records, four veterinary and none testing injected glutathione as an intervention in healthy adults. Run 2026-08-07. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+subcutaneous%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England journal of medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. The New England journal of medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Novo Nordisk A/S; Eli Lilly and Company (2026). STEP 1, NCT03548935 — phase 3, completed, enrolment 1,961; and SURMOUNT-1, NCT04184622 — phase 3, completed, enrolment 2,539. Both read 2026-08-07. ClinicalTrials.gov (US National Library of Medicine). https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.